Comparison / Study ID (number of participants)	Outcome	RR	95% CI lower limit	95% CI upper limit
Rabbit ATG Fresenius versus rabbit ATG Merieux
Norrby 1997 (90)	Acute rejection	0.87	0.63	1.20
	CMV infection	0.56	0.29	1.07
ALG versus ATG
Toledo‐Pereyra 1985 (50)	Death at 1 year	0.5	0.10	2.49
	Graft loss at 1 year	0.92	0.50	1.67
	Acute rejection	0.95	0.73	1.24
	Thrombocytopenia	1	0.15	6.55
	Leucopenia	0.07	0	1.11
	HSV infection	2	0.19	20.67
ALG vs OKT3 (given only if delayed graft functionpost‐operatively)
Steinmuller 1991 (51)	Death at 6 months	0.48	0.05	4.98
	Graft loss (all cause) at 6 months	0.96	0.27	3.43
	Acute rejection	0.61	0.28	1.32
	Side effects (any reported)	0.41	0.24	0.72
	Any infection	0.89	0.51	1.55
	CMV	0.89	0.51	1.55
Anti‐CD7 versus OKT3
Lazarovits 1993 (20)	Death 5 years	1	0.07	13.87
	Graft loss 5 years	0.11	0.01	1.83
	Acute rejection	1.4	0.67	2.94
	Serious infection	0.25	0.03	1.86
Anti‐CD2 rat monoclonal antibody versus no induction
Squifflet 1997 (40)	Death at 6 months	0.2	0.01	3.92
	Graft loss (death censored) at 6 months	0 events	Not estimable
	Acute rejection	0.42	0.18	0.96
	Delayed graft function	0.17	0.02	1.26
	Bacterial infection	0.25	0.03	2.05
	CMV	0.5	0.05	5.08
	EB virus	3	0.13	69.52
	Herpes Simplex virus	4	0.49	32.72
	Other viral infection	0.33	0.01	7.72
	Malignancy	3	0.13	69.52
	Graft function at 6 months (SCr, µmol/L)	8*	‐20.99	36.99
Anti‐LFA‐1 monoclonal antibody versus no induction1
Spillner 1998 (22)	Death at 1 year	3	0.14	66.53
	Graft loss (all cause) at 1 year	1	0.17	5.89
	Serious infection	1	0.07	14.05
	CMV infection	1	0.17	5.89
	Delayed graft function	1.5	0.31	7.3
	Graft function at 1 year (SCr, µmol/L)	‐17.6*	‐62.69	27.49
Anti‐LFA‐1 monoclonal antibody versus ATG
Hourmant 1996 (101)	Death at 1 year	4.72	0.23	95.86
	Graft loss (death censored) at 1 year	0.39	0.08	1.93
	Acute rejection	1.05	0.62	1.78
	Delayed graft function	0.55	0.28	1.09
	Any episode of infection	1.05	0.74	1.48
	CMV disease	0.94	0.5	1.77
	Treatment stopped due to side effects	0.24	0.03	2.04
	Leucopenia	0.4	0.11	1.47
	Thrombocytopenia	0.57	0.22	1.44
	Fever (1st 10 days)	0.58	0.36	0.94
Anti‐ICAM‐1 monoclonal antibody versus placebo
EARTS Study 1999 (266)	Death at 1 year	1.71	0.7	4.22
	Graft loss at 1 year	1.4	0.76	2.59
	Acute rejection at 3 months	1.18	0.88	1.57
	Acute rejection at 1 year	1.07	0.82	1.41
	Primary non function	1.2	0.38	3.83
	Delayed graft function	1.21	0.82	1.77
	Any infection	1.13	0.98	1.3
	Sepsis	1.3	0.59	2.86
	Malignancy	0.5	0.05	5.45
ATG versus ATG + rituximab vs ATG + bortezomib versus ATG + rituximab + bortezomib
Ejaz 2013 (40)	**	‐	‐	‐